Wells Fargo lowered the firm’s price target on GoodRx (GDRX) to $8 from $9 and keeps an Overweight rating on the shares. The firm says that while some end market noise persists, GoodRx appears to be stabilizing fundamentals and showing consistency across the enterprise. Wells notes some growth initiatives pan out slower than expected, but risk/reward feels balanced to the upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX: